The DOI matches its Crossref record; 324 of the 324 references it cites were found in a registry or an index.
Cannabinoids and Epilepsy
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 3×
“The cannabinoid type 1 (CB1R) and type 2 (CB2R) receptors, which bindΔ9-THC, were cloned in the 1990s [25, 26], supporting an endogenous system for this principal cannabinoid’s pharmacological activity.”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Fisher, R. S., Boas, W. V. E., Blume, W., Elger, C., Genton, P., Lee, P., & Engel, J. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.66104.x · Cited by 3,671
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“These endocannabinoids were identified as the hydrophobic ligands N-arachidonoyl ethanolamide (anandamide) [32] and 2-arachidonoyl glycerol (2-AG) [33, 34].”
BackgroundAdverse health effects of marijuana use.
Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1402309 · Cited by 2,774
Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
Beghi, E., Berg, A., Carpio, A., Forsgren, L., Hesdorffer, D. C., Hauser, W. A., Malmgren, K., Shinnar, S., Temkin, N., Thurman, D., et al. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.00273_1.x · Cited by 2,296
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“and long-term depression (for a review, see [62, 63]).”
BackgroundThe role of inflammation in epilepsy
Vezzani, A., French, J., Bartfai, T., & Baram, T. Z. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.178 · Cited by 1,876 · cited 1×
“Given the synergistic relation between seizures and inflammation [100–102], the cannabinoid system provides a novel strategy to target both segments of this feedback cycle.”
BackgroundFormation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568 · cited 1×
“GPR55 was initially characterized as a novel cannabinoid receptor, coupled to Gα13 [114].”
BackgroundTaming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Bisogno, T., Hanuš, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Di Marzo, V. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,311
Synergy research: approaching a new generation of phytopharmaceuticals.
Wagner, H., & Ulrich-Merzenich, G. (2009) · Phytomedicine · doi:10.1016/j.phymed.2008.12.018 · Cited by 1,296
Shepard, T. H. (1981) · Teratology · doi:10.1002/tera.1420230118 · Cited by 1,296
Katona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218 · cited 2×
“parvalbumin-negative GABAergic interneurons [64–66].”
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & RIO-North America Study Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,218
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208 · cited 3×
“Kainic acid (KA) (30 mg/kg)-induced seizures increased levels of the anandamide in wild-type mice (20 min postinjection) [146], and pilocarpine (375 mg/kg)-induced seizures increased levels of 2-AG (15 min postseizure onset) [147].”
BackgroundChemical constituents of marijuana: The complex mixture of natural cannabinoids
ElSohly, M. A., & Slade, D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.011 · Cited by 1,094 · cited 1×
“The cannabis plant consists contains >100 C21 terpenophenolic compounds, known collectively as phytocannabinoids [72].”
BackgroundKwan, P., Schachter, S. C., & Brodie, M. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004418 · Cited by 1,052
Devinsky, O., Cilio, M. R., Cross, H., Fernandez‐Ruiz, J., French, J., Hill, C., Katz, R., Di Marzo, V., Jutras‐Aswad, D., Notcutt, W. G., et al. (2014) · Epilepsia · doi:10.1111/epi.12631 · Cited by 1,000 · cited 3×
“models of seizure with low toxicity and high tolerability [11].”
BackgroundSelf-citationDe Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Marsicano, G., & Lutz, B. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00847.x · Cited by 937
Löscher, W. (2011) · Seizure · doi:10.1016/j.seizure.2011.01.003 · Cited by 932
Synergism between natural products and antibiotics against infectious diseases
Hemaiswarya, S., Kruthiventi, A. K., & Doble, M. (2008) · Phytomedicine · doi:10.1016/j.phymed.2008.06.008 · Cited by 916
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878
Kreitzer, A. C., & Regehr, W. G. (2001) · Neuron · doi:10.1016/s0896-6273(01)00246-x · Cited by 875
Glia and epilepsy: excitability and inflammation
Devinsky, O., Vezzani, A., Najjar, S., De Lanerolle, N. C., & Rogawski, M. A. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.008 · Cited by 867
Self-citationThe Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0009 · Cited by 865
Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants
Hampson, A. J., Grimaldi, M., Axelrod, J., & Wink, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8268 · Cited by 850 · cited 1×
“Δ9-THC has antioxidant effects inαamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid- and N-methyl-D-aspartate-mediated cytotoxicity models via a CB1R-independent mechanism [87].”
BackgroundENDOCANNABINOID-MEDIATED SYNAPTIC PLASTICITY IN THE CNS
Chevaleyre, V., Takahashi, K. A., & Castillo, P. E. (2006) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.112834 · Cited by 783
Crean, R. D., Crane, N. A., & Mason, B. J. (2011) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31820c23fa · Cited by 732
Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action
Di Marzo, V., Melck, D., Bisogno, T., & De Petrocellis, L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01283-1 · Cited by 712
GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current
Lauckner, J. E., Jensen, J. B., Chen, H.-Y., Lu, H.-C., Hille, B., & Mackie, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711278105 · Cited by 712
Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications
Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., & Huestis, M. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.005 · Cited by 709
The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus
Monory, K., Massa, F., Egertová, M., Eder, M., Blaudzun, H., Westenbroek, R., Kelsch, W., Jacob, W., Marsch, R., Ekker, M., et al. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.006 · Cited by 706
Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells.
Mackie, K., & Hille, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3825 · Cited by 694
Modulation of transmitter release via presynaptic cannabinoid receptors
Schlicker, E., & Kathmann, M. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01805-8 · Cited by 671
Arroyo, S., Rumià, J., Martínez, I., & Ribalta, T. (1998) · PubMed · Cited by 652
Glass, M., & Felder, C. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-14-05327.1997 · Cited by 635
Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M.-H., Vogel, Z., Bisogno, T., De Petrocellis, L., Di Marzo, V., & Mechoulam, R. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00392-6 · Cited by 629
The core Dravet syndrome phenotype
Dravet, C. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.02994.x · Cited by 627
Mackie, K., Lai, Y., Westenbroek, R., & Mitchell, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-10-06552.1995 · Cited by 626
Russo, E., & Guy, G. W. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.08.026 · Cited by 610
Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids
E. Alger, B. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00080-1 · Cited by 598
Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589
Endocannabinoid signaling as a synaptic circuit breaker in neurological disease
Katona, I., & Freund, T. F. (2008) · Nature Medicine · doi:10.1038/nm.f.1869 · Cited by 579
The effects of adolescent cannabis use on educational attainment: a review
Lynskey, M., & Hall, W. (2000) · Addiction · doi:10.1046/j.1360-0443.2000.951116213.x · Cited by 571
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., & Mechoulam, R. (2008) · Pharmacology · doi:10.1159/000137430 · Cited by 568
Incidence and risk factors in sudden unexpected death in epilepsy: A prospective cohort study
Walczak, T. S., Leppik, I. E., D’Amelio, M., Rarick, J., So, E., Ahman, P., Ruggles, K., Cascino, G. D., Annegers, J. F., & Hauser, W. A. (2001) · Neurology · doi:10.1212/wnl.56.4.519 · Cited by 545
Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons
Twitchell, W., Brown, S., & Mackie, K. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.78.1.43 · Cited by 544
Presynaptic Specificity of Endocannabinoid Signaling in the Hippocampus
Wilson, R. I., Kunos, G., & Nicoll, R. A. (2001) · Neuron · doi:10.1016/s0896-6273(01)00372-5 · Cited by 544
Risk factors for sudden unexpected death in epilepsy: a case control study
Nilsson, L., Farahmand, B., Persson, P.-G., Thiblin, I., & Tomson, T. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05114-9 · Cited by 522
Molecular Composition of the Endocannabinoid System at Glutamatergic Synapses
Katona, I., Urbán, G. M., Wallace, M., Ledent, C., Jung, K.-M., Piomelli, D., Mackie, K., & Freund, T. F. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0309-06.2006 · Cited by 511
Activation of Corticotropin-Releasing Factor in the Limbic System During Cannabinoid Withdrawal
Rodrı́guez de Fonseca, F., Carrera, M. R. A., Navarro, M., Koob, G. F., & Weiss, F. (1997) · Science · doi:10.1126/science.276.5321.2050 · Cited by 499
Carrier, E. J., Auchampach, J. A., & Hillard, C. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511232103 · Cited by 497
Kawamura, Y., Fukaya, M., Maejima, T., Yoshida, T., Miura, E., Watanabe, M., Ohno-Shosaku, T., & Kano, M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4872-05.2006 · Cited by 489
Mechoulam, R., & Shvo, Y. (1963) · Tetrahedron · doi:10.1016/0040-4020(63)85022-x · Cited by 486
Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Nelson, R. A., Moolchan, E. T., & Frank, R. A. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.4.322 · Cited by 481
Synaptic‐ and agonist‐induced excitatory currents of Purkinje cells in rat cerebellar slices.
Llano, I., Marty, A., Armstrong, C. M., & Konnerth, A. (1991) · The Journal of Physiology · doi:10.1113/jphysiol.1991.sp018465 · Cited by 481
Hermanns‐Clausen, M., Kneisel, S., Szabo, B., & Auwärter, V. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04078.x · Cited by 479
Cannabinoids and Neuroprotection in Global and Focal Cerebral Ischemia and in Neuronal Cultures
Nagayama, T., Sinor, A. D., Simon, R. P., Chen, J., Graham, S. H., Jin, K., & Greenberg, D. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-08-02987.1999 · Cited by 468
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Englund, A., Morrison, P. D., Nottage, J., Hague, D., Kane, F., Bonaccorso, S., Stone, J. M., Reichenberg, A., Brenneisen, R., Holt, D., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112460109 · Cited by 462
Identification of GPR55 as a lysophosphatidylinositol receptor
Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., & Sugiura, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.078 · Cited by 459
Postsynaptic spike firing reduces synaptic GABAA responses in hippocampal pyramidal cells
Pitler, T., & Alger, B. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-10-04122.1992 · Cited by 414
Marijuana and medicine: assessing the science base
(1999) · Choice Reviews Online · doi:10.5860/choice.37-2206 · Cited by 410
Qin, N., Neeper, M. P., Liu, Y., Hutchinson, T. L., Lubin, M. L., & Flores, C. M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0504-08.2008 · Cited by 396
Wallace, M. J., Blair, R. E., Falenski, K. W., Martin, B. R., & DeLorenzo, R. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051920 · Cited by 393
Patsalos, P. N., & Perucca, E. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00483-6 · Cited by 391
Quantitative Methods for Assessing Drug Synergism
Tallarida, R. J. (2011) · Genes & Cancer · doi:10.1177/1947601912440575 · Cited by 378
Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation
Ehrhart, J., Obregon, D., Mori, T., Hou, H., Sun, N., Bai, Y., Klein, T., Fernandez, F., Tan, J., & Shytle, R. D. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-29 · Cited by 377
Dewey, W. L. (1987) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(87)90061-4 · Cited by 375
Robbe, D., Alonso, G., Duchamp, F., Bockaert, J., & Manzoni, O. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00109.2001 · Cited by 366
Gaoni, Y., & Mechoulam, R. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00730a036 · Cited by 364
Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., & Izzo, A. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02327.x · Cited by 361
Porter, B. E., & Jacobson, C. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.08.037 · Cited by 359
Cerebellar Depolarization-Induced Suppression of Inhibition Is Mediated by Endogenous Cannabinoids
Kreitzer, A. C., & Regehr, W. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-20-j0005.2001 · Cited by 358
The cannabis withdrawal syndrome
Budney, A. J., & Hughes, J. R. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000218592.00689.e5 · Cited by 349
Sugiura, T., Kobayashi, Y., Oka, S., & Waku, K. (2002) · Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) · doi:10.1054/plef.2001.0356 · Cited by 348
Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo
Jones, N. A., Hill, A. J., Smith, I., Bevan, S. A., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.159145 · Cited by 347
Self-citationStout, S. M., & Cimino, N. M. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.849268 · Cited by 347
Shohami, E., Gallily, R., Mechoulam, R., Bass, R., & Ben-Hur, T. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00181-6 · Cited by 337
De Petrocellis, L., Vellani, V., Schiano-Moriello, A., Marini, P., Magherini, P. C., Orlando, P., & Di Marzo, V. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.134809 · Cited by 336
Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I., & Watanabe, K. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.05.018 · Cited by 322
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312 · cited 1×
“These effects can be tested in vitro or in vivo using assays such as the isobolographic approach [141, 142].”
MethodSelf-citationSim, L. J., Hampson, R. E., Deadwyler, S. A., & Childers, S. R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-24-08057.1996 · Cited by 312
Esposito, G., Scuderi, C., Savani, C., Steardo, L., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V, & Steardo, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707337 · Cited by 308 · cited 1×
“[127–129].”
Internalization and Recycling of the CB1 Cannabinoid Receptor
Hsieh, C., Brown, S., Derleth, C., & Mackie, K. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730493.x · Cited by 296
The enigmatic pharmacology of GPR55
Ross, R. A. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.004 · Cited by 296
Cannabinoid CB2 receptors in human brain inflammation
Benito, C., Tolón, R. M., Pazos, M. R., Núñez, E., Castillo, A. I., & Romero, J. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707505 · Cited by 291
Lisdahl, K. M., Gilbart, E. R., Wright, N. E., & Shollenbarger, S. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00053 · Cited by 284
Caulfield, M. P., & Brown, D. A. (1992) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1992.tb14321.x · Cited by 278
The case for medical marijuana in epilepsy
Maa, E., & Figi, P. (2014) · Epilepsia · doi:10.1111/epi.12610 · Cited by 275
Breivogel, C. S., Childers, S. R., Deadwyler, S. A., Hampson, R. E., Vogt, L. J., & Sim‐Selley, L. J. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0732447.x · Cited by 273
Regulation of Cannabinoid CB1 Receptors in the Central Nervous System by Chronic Cannabinoids
Sim-Selley, L. J. (2003) · Critical Reviews in Neurobiology · doi:10.1615/critrevneurobiol.v15.i2.10 · Cited by 271
Staton, P. C., Hatcher, J. P., Walker, D. J., Morrison, A. D., Shapland, E. M., Hughes, J. P., Chong, E., Mander, P. K., Green, P. J., Billinton, A., et al. (2008) · Pain · doi:10.1016/j.pain.2008.04.006 · Cited by 270 · cited 1×
“Finally, treatment of microglial cultures with interferon-γ raised mRNA levels of the CBD receptor GPR55 [130], which regulates the inflammatory responses to neuropathic pain [131].”
BackgroundCLINICAL STUDIES OF CANNABIS TOLERANCE AND DEPENDENCE*
Jones, R. T., Benowitz, N., & Bachman, J. (1976) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1976.tb49901.x · Cited by 270
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266
Phytochemical and genetic analyses of ancient Cannabis from Central Asia.
Russo, E. B., Jiang, H.-E., Li, X., Sutton, A., Carboni, A., del Bianco, F., Mandolino, G., Potter, D. J., Zhao, Y.-X., Bera, S., et al. (2008) · Journal of Experimental Botany · doi:10.1093/jxb/ern260 · Cited by 261
Patients with Refractory Seizures
Devinsky, O. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905203402008 · Cited by 257
Self-citationTortoriello, G., Morris, C. V., Alpar, A., Fuzik, J., Shirran, S. L., Calvigioni, D., Keimpema, E., Botting, C. H., Reinecke, K., Herdegen, T., et al. (2014) · The EMBO Journal · doi:10.1002/embj.201386035 · Cited by 255
Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+Levels
Ryan, D., Drysdale, A. J., Lafourcade, C., Pertwee, R. G., & Platt, B. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4212-08.2009 · Cited by 255
Melis, M., Perra, S., Muntoni, A. L., Pillolla, G., Lutz, B., Marsicano, G., Di Marzo, V., Gessa, G. L., & Pistis, M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3502-04.2004 · Cited by 253
Gilman, J. M., Kuster, J. K., Lee, S., Lee, M. J., Kim, B. W., Makris, N., van der Kouwe, A., Blood, A. J., & Breiter, H. C. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4745-13.2014 · Cited by 250
Molecular Components and Functions of the Endocannabinoid System in Mouse Prefrontal Cortex
Lafourcade, M., Elezgarai, I., Mato, S., Bakiri, Y., Grandes, P., & Manzoni, O. J. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000709 · Cited by 249
Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells
Puffenbarger, R. A., Boothe, A. C., & Cabral, G. A. (2000) · Glia · doi:10.1002/(sici)1098-1136(20000101)29:1<58::aid-glia6>3.0.co;2-w · Cited by 248
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
Jones, N. A., Glyn, S. E., Akiyama, S., Hill, T. D. M., Hill, A. J., Weston, S. E., Burnett, M. D. A., Yamasaki, Y., Stephens, G. J., Whalley, B. J., et al. (2012) · Seizure · doi:10.1016/j.seizure.2012.03.001 · Cited by 248
Self-citationBooz, G. W. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.01.007 · Cited by 245
Ludányi, A., Erőss, L., Czirják, S., Vajda, J., Halász, P., Watanabe, M., Palkovits, M., Maglóczky, Z., Freund, T. F., & Katona, I. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4465-07.2008 · Cited by 243
Deadwyler, S. A., Hampson, R. E., Mu, J., Whyte, A., & Childers, S. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09495-9 · Cited by 241
GPR55: a new member of the cannabinoid receptor clan?
Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707464 · Cited by 240
Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists
Thomas, B. F., Gilliam, A. F., Burch, D. F., Roche, M. J., & Seltzman, H. H. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37365-3 · Cited by 240
El-Remessy, A. B., Khalil, I. E., Matragoon, S., Abou-Mohamed, G., Tsai, N.-J., Roon, P., Caldwell, R. B., Caldwell, R. W., Green, K., & Liou, G. I. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63558-4 · Cited by 235
Brown, S. P., Brenowitz, S. D., & Regehr, W. G. (2003) · Nature Neuroscience · doi:10.1038/nn1126 · Cited by 234
Gloss, D., & Vickrey, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009270.pub3 · Cited by 231
Cannabinoids and brain injury: therapeutic implications
Mechoulam, R. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02276-1 · Cited by 229
Russo, E. B., Guy, G. W., & Robson, P. J. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790150 · Cited by 228
Cell-specific STORM super-resolution imaging reveals nanoscale organization of cannabinoid signaling
Dudok, B., Barna, L., Ledri, M., Szabó, S. I., Szabadits, E., Pintér, B., Woodhams, S. G., Henstridge, C. M., Balla, G. Y., Nyilas, R., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3892 · Cited by 227 · cited 1×
“parvalbumin-negative GABAergic interneurons [64–66].”
Cannabis with high cannabidiol content is associated with fewer psychotic experiences
Schubart, C. D., Sommer, I. E. C., van Gastel, W. A., Goetgebuer, R. L., Kahn, R. S., & Boks, M. P. M. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.017 · Cited by 226
Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects
Wallace, M. J., Wiley, J. L., Martin, B. R., & DeLorenzo, R. J. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01243-2 · Cited by 226
Esposito, G., De Filippis, D., Maiuri, M. C., De Stefano, D., Carnuccio, R., & Iuvone, T. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.01.047 · Cited by 225
Yamaori, S., Ebisawa, J., Okushima, Y., Yamamoto, I., & Watanabe, K. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.02.017 · Cited by 223
Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy
Press, C. A., Knupp, K. G., & Chapman, K. E. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.02.043 · Cited by 223
De Petrocellis, L., & Di Marzo, V. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9177-z · Cited by 217
The Cannabinoid System and Cytokine Network
Klein, T. W., Lane, B., Newton, C. A., & Friedman, H. (2000) · Proceedings of the Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.2000.22501.x · Cited by 214
Δ9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism
Lichtman, A. H., & Martin, B. R. (1996) · Psychopharmacology · doi:10.1007/bf02246347 · Cited by 213
Sylantyev, S., Jensen, T. P., Ross, R. A., & Rusakov, D. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211204110 · Cited by 213
Severe Toxicity Following Synthetic Cannabinoid Ingestion
Lapoint, J., James, L. P., Moran, C. L., Nelson, L. S., Hoffman, R. S., & Moran, J. H. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.609822 · Cited by 212
Quality-of-life trajectories in epilepsy: A review of the literature
Jacoby, A., & Baker, G. A. (2008) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2007.11.013 · Cited by 211
Pertwee, R. G. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.7.1553 · Cited by 208
Wallace, M. J., Martin, B. R., & DeLorenzo, R. J. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02331-2 · Cited by 206
Long-Term Plasticity of Endocannabinoid Signaling Induced by Developmental Febrile Seizures
Chen, K., Ratzliff, A., Hilgenberg, L., Gulyás, A., Freund, T. F., Smith, M., Dinh, T. P., Piomelli, D., Mackie, K., & Soltesz, I. (2003) · Neuron · doi:10.1016/s0896-6273(03)00499-9 · Cited by 204
Neuroprotective Antioxidants from Marijuanaa
HAMPSON, A. J., GRIMALDI, M., LOLIC, M., WINK, D., ROSENTHAL, R., & AXELROD, J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06193.x · Cited by 203
Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19
Jiang, R., Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-129 · Cited by 199
Inhibition of Recombinant Human T-type Calcium Channels by Δ9-Tetrahydrocannabinol and Cannabidiol
Ross, H. R., Napier, I., & Connor, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707104200 · Cited by 199
Molina-Holgado, F., Pinteaux, E., Moore, J. D., Molina-Holgado, E., Guaza, C., Gibson, R. M., & Rothwell, N. J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-16-06470.2003 · Cited by 192
Clinical Relevance of Cannabis Tolerance and Dependence
JONES, R. T., BENOWITZ, N. L., & HERNING, R. I. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02589.x · Cited by 191
McAllister, S. D., Griffin, G., Satin, L. S., & Abood, M. E. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35147-x · Cited by 190
ROG, D., NURMIKKO, T., & YOUNG, C. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.09.013 · Cited by 187
Hill, T. D. M., Cascio, M., Romano, B., Duncan, M., Pertwee, R. G., Williams, C. M., Whalley, B. J., & Hill, A. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12321 · Cited by 187
Self-citationSeizures associated with recreational drug abuse
Alldredge, B. K., Lowenstein, D. H., & Simon, R. P. (1989) · Neurology · doi:10.1212/wnl.39.8.1037 · Cited by 185
Pharmacological interaction between cannabidiol and ?9-tetrahydrocannabinol
Karniol, I. G., & Carlini, E. A. (1973) · Psychopharmacologia · doi:10.1007/bf00428793 · Cited by 182
Comparison of smoked marijuana and oral Δ 9 -tetrahydrocannabinol in humans
Hart, C., Ward, A., Haney, M., Comer, S., Foltin, R., & Fischman, M. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1231-y · Cited by 180
Alcohol and Marijuana: Effects on Epilepsy and Use by Patients with Epilepsy
Gordon, E., & Devinsky, O. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.19301.x · Cited by 179
Self-citationOviedo, A., Glowa, J., & Herkenham, M. (1993) · Brain Research · doi:10.1016/0006-8993(93)90220-h · Cited by 179
Placebo effects in children: a review
Weimer, K., Gulewitsch, M. D., Schlarb, A. A., Schwille-Kiuntke, J., Klosterhalfen, S., & Enck, P. (2013) · Pediatric Research · doi:10.1038/pr.2013.66 · Cited by 178
Mallet, P. E., & Beninger, R. J. (1998) · Psychopharmacology · doi:10.1007/s002130050733 · Cited by 178
Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity
Gruber, S. A., Dahlgren, M. K., Sagar, K. A., Gönenç, A., & Lukas, S. E. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3326-z · Cited by 177
van der Stelt, M., Veldhuis, W. B., Bär, P. R., Veldink, G. A., Vliegenthart, J. F. G., & Nicolay, K. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06475.2001 · Cited by 176
Agonist-Induced Internalization and Trafficking of Cannabinoid CB1Receptors in Hippocampal Neurons
Coutts, A. A., Anavi-Goffer, S., Ross, R. A., MacEwan, D. J., Mackie, K., Pertwee, R. G., & Irving, A. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-07-02425.2001 · Cited by 175
De Fonseca, F. R., Gorriti, M. A., Fernández-Ruiz, J. J., Palomo, T., & Ramos, J. A. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90108-2 · Cited by 175
Henry, D. J., & Chavkin, C. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11289-9 · Cited by 173
Tsou, K., Patrick, S. L., & Walker, J. M. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00360-w · Cited by 173
Cannabidivarin is anticonvulsant in mouse and rat
Hill, A., Mercier, M., Hill, T., Glyn, S., Jones, N., Yamasaki, Y., Futamura, T., Duncan, M., Stott, C., Stephens, G., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02207.x · Cited by 172
Self-citationLiou, G. I., Auchampach, J. A., Hillard, C. J., Zhu, G., Yousufzai, B., Mian, S., Khan, S. H., & Khalifa, Y. M. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2196 · Cited by 170
Cannabis, cannabidiol, and epilepsy — From receptors to clinical response
Szaflarski, J. P., & Bebin, E. M. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2014.08.135 · Cited by 168
From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis
Mechoulam, R., & Ben‐Shabat, S. (1999) · Natural Product Reports · doi:10.1039/a703973e · Cited by 167
Placebo effect of medication cost in Parkinson disease: A randomized double-blind study
Espay, A. J., Norris, M. M., Eliassen, J. C., Dwivedi, A. K., Smith, M. S., Banks, C., Allendorfer, J. B., Lang, A. E., Fleck, D. E., Linke, M. J., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001282 · Cited by 167
Yamaori, S., Kushihara, M., Yamamoto, I., & Watanabe, K. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.01.028 · Cited by 165
Dewey, W. L. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06864-4 · Cited by 165
Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6
Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.041384 · Cited by 164
Biochemistry of the Endogenous Ligands of Cannabinoid Receptors
Marzo, V. D., & Deutsch, D. G. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0214 · Cited by 164
Cannabinoids modulate potassium current in cultured hippocampal neurons.
Deadwyler, S. A., Hampson, R. E., Bennett, B. A., Edwards, T. A., Mu, J., Pacheco, M. A., Ward, S. J., & Childers, S. R. (1993) · PubMed · Cited by 164
Refractory epilepsy: a progressive, intractable but preventable condition?
Kwan, P., & Brodie, M. J. (2002) · Seizure · doi:10.1053/seiz.2002.0593 · Cited by 161
Differential effects of Δ 9 -THC on spatial reference and working memory in mice
S., V., R., H., B., M., & A., L. (2001) · Psychopharmacology · doi:10.1007/s002130100780 · Cited by 160
Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells
Drysdale, A. J., Ryan, D., Pertwee, R. G., & Platt, B. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.11.008 · Cited by 160
Rheims, S., Cucherat, M., Arzimanoglou, A., & Ryvlin, P. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050166 · Cited by 159
Chen, K., Neu, A., Howard, A. L., Földy, C., Echegoyen, J., Hilgenberg, L., Smith, M., Mackie, K., & Soltesz, I. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3966-06.2007 · Cited by 158
Maejima, T., Ohno‐Shosaku, T., & Kano, M. (2001) · Neuroscience Research · doi:10.1016/s0168-0102(01)00241-3 · Cited by 157
Differential changes in GPR55 during microglial cell activation
Pietr, M., Kozela, E., Levy, R., Rimmerman, N., Lin, Y. H., Stella, N., Vogel, Z., & Juknat, A. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.05.028 · Cited by 155
Ahrens, J., Demir, R., Leuwer, M., de la Roche, J., Krampfl, K., Foadi, N., Karst, M., & Haeseler, G. (2009) · Pharmacology · doi:10.1159/000201556 · Cited by 154
Romero, J., García‐Palomero, E., Castro, J. G., García-Gil, L., Ramos, J. A., & Fernández‐Ruíz, J. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(96)00277-x · Cited by 150
Villares, J. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.11.012 · Cited by 150
Molina‐Holgado, F., Molina‐Holgado, E., Guaza, C., & Rothwell, N. J. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10165 · Cited by 148
Distribution of type 1 cannabinoid receptor (CB1)‐immunoreactive axons in the mouse hypothalamus
Wittmann, G., Deli, L., Kalló, I., Hrabovszky, E., Watanabe, M., Liposits, Z., & Fekete, C. (2007) · The Journal of Comparative Neurology · doi:10.1002/cne.21383 · Cited by 146
Anticonvulsant Activity of N‐Palmitoylethanolamide, a Putative Endocannabinoid, in Mice
Lambert, D. M., Vandevoorde, S., Diependaele, G., Govaerts, S. J., & Robert, A. R. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.41499.x · Cited by 145
Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice
Consroe, P. F., Benedito, M. A. C., Leite, J. R., Carlini, E. A., & Mechoulam, R. (1982) · European Journal of Pharmacology · doi:10.1016/0014-2999(82)90264-3 · Cited by 142
Toward drugs derived from cannabis
Mechoulam, R., & Carlini, E. A. (1978) · Die Naturwissenschaften · doi:10.1007/bf00450585 · Cited by 140
Adenosine–cannabinoid receptor interactions. Implications for striatal function
Ferré, S., Lluís, C., Justinová, Z., Quiroz, C., Orrù, M., Navarro, G., Canela, E. I., Franco, R., & Goldberg, S. R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00723.x · Cited by 138
Karanian, D. A., Brown, Q. B., Makriyannis, A., Kosten, T. A., & Bahr, B. A. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2347-05.2005 · Cited by 134
Sim‐Selley, L. J., Schechter, N. S., Rorrer, W. K., Dalton, G. D., Hernandez, J., Martin, B. R., & Selley, D. E. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.019612 · Cited by 134
Epilepsy: its Symptoms, Treatment, and Relation to other Chronic, Convulsive Diseases
Reynolds, J. R. (1862) · American Journal of Psychiatry · doi:10.1176/ajp.19.2.198 · Cited by 134
Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A
Aceto, M. D. G., Scates, S. M., Lowe, J. A., III, & Martin, B. R. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00447-s · Cited by 131
Signaling pathways involved in the development of cannabinoid tolerance
Martin, B. R., Sim‐Selley, L. J., & Selley, D. E. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.04.005 · Cited by 128
Abood, M. E., Rizvi, G., Sallapudi, N., & McAllister, S. D. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02065-1 · Cited by 127
Romero, J., Berrendero, F., Manzanares, J., P�rez, A., Corchero, J., Fuentes, J., Fern�ndez-Ruiz, J. J., & Ramos, J. A. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199811)30:3<298::aid-syn7>3.0.co;2-6 · Cited by 126
The challenge and promise of anti-epileptic therapy development in animal models
Simonato, M., Brooks‐Kayal, A. R., Engel, J., Galanopoulou, A. S., Jensen, F. E., Moshé, S. L., O'Brien, T. J., Pitkänen, A., Wilcox, K. S., & French, J. A. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70076-6 · Cited by 126
Silva, G. E. D., & Takahashi, R. N. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00275-5 · Cited by 125
Sim‐Selley, L. J., & Martin, B. R. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035618 · Cited by 125
Inflammation and Epilepsy: The Foundations for a New Therapeutic Approach in Epilepsy?
Walker, L. E., & Sills, G. J. (2012) · Epiliepsy currents/Epilepsy currents · doi:10.5698/1535-7511-12.1.8 · Cited by 120
Placebo response in asthma: A robust and objective phenomenon
Kemeny, M. E., Rosenwasser, L. J., Panettieri, R. A., Rose, R. M., Berg-Smith, S. M., & Kline, J. N. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.03.016 · Cited by 116
Romigi, A., Bari, M., Placidi, F., Marciani, M. G., Malaponti, M., Torelli, F., Izzi, F., Prosperetti, C., Zannino, S., de la Corte, F. G., et al. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02334.x · Cited by 115
Dependence on tetrahydrocannabinol in rhesus monkeys.
Beardsley, P. M., Balster, R. L., & Harris, L. S. (1986) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23582-0 · Cited by 115
Marihuana, the First Twelve Thousand Years
Abel, E. L. (1980) · Cited by 115
Cited by
The pharmacokinetics and the pharmacodynamics of cannabinoids
Lucas, C. J., Galettis, P., & Schneider, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13710 · Cited by 724
Cannabidiol: State of the art and new challenges for therapeutic applications
Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 614
Interactions between cannabidiol and commonly used antiepileptic drugs
Gaston, T. E., Bebin, E. M., Cutter, G. R., Liu, Y., Szaflarski, J. P., & Program, T. U. C. (2017) · Epilepsia · doi:10.1111/epi.13852 · Cited by 349
Abrams, D. I. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.003 · Cited by 296
Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals
Legare, C. A., Raup-Konsavage, W. M., & Vrana, K. E. (2022) · Pharmacology · doi:10.1159/000521683 · Cited by 275
Metadata
- Authors
- Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 12
- Issue
- 4
- Pages
- 747-768
- ISSN
- 1878-7479 (ISSN-L)
- OpenAlex
- W1853642699
- Cited by
- 276
- References
- 324
- FWCI
- 16.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.